CGTX

Business Context and Reporting Period

Cognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company developing disease-modifying therapies for age-related degenerative diseases of the central nervous system and retina. The company's lead product candidate is zervimesine (CT1812), targeting the sigma-2 receptor complex. This Form 10-Q covers the quarterly period ended March 31, 2025. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.

Key Financial Metrics

Liquidity and Debt: The company has no long-term debt. Total liabilities were $11.2 million as of March 31, 2025, primarily consisting of accrued expenses ($7.7 million) and operating lease liabilities. The company maintains an At-The-Market (ATM) sales agreement with $20.4 million remaining capacity and an equity line with Lincoln Park Capital with $34.8 million available.

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss decreased by $671,000 (7.3%) compared to Q1 2024, driven by a reduction in operating expenses and the absence of a currency translation loss recorded in the prior year.
• Operating Expenses: Total operating expenses decreased by $327,000 to $13.8 million. Research and Development (R&D) expenses increased slightly by $233,000 due to higher clinical trial activities, while General and Administrative (G&A) expenses decreased by $560,000, primarily due to lower stock-based compensation.
• Cash Position: Cash and cash equivalents declined by $8.6 million during the quarter, resulting in a cash balance of $16.4 million. This decrease was driven by net cash used in operating activities of $9.9 million, partially offset by $1.3 million in financing proceeds from ATM sales.
• Grant Receivables: Grant receivables increased by $2.1 million to $4.8 million, reflecting the timing of reimbursements from the National Institute of Aging (NIA).

Guidance, Outlook, and Risks

Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months. As of May 7, 2025, the company believes its cash balance is insufficient to fund operations through one year after the filing date without additional financing.

Strategic Updates:

• Alzheimer's Disease (AD): The Phase 2 SHINE study met primary endpoints for safety. Subgroup analysis indicated a 95% reduction in cognitive decline for patients with low baseline plasma p-tau217. The Phase 2 START study is ongoing.
• Dementia with Lewy Bodies (DLB): The Phase 2 SHIMMER study met primary endpoints for safety and showed significant improvements in behavioral, functional, cognitive, and motor scales.
• Geographic Atrophy (GA): The company voluntarily discontinued the Phase 2 MAGNIFY study in January 2025 to focus resources on AD and DLB programs. The discontinuation was not due to safety concerns.

Risks and Contingencies:

• Capital Requirements: The company requires substantial additional funding to continue operations and clinical development. Failure to secure funding could force delays or termination of programs.
• Regulatory Uncertainty: Risks include potential disruptions to FDA staffing and funding due to government shutdowns or policy changes under the new U.S. administration.
• Grant Dependency: A significant portion of funding relies on NIA grants, which are subject to political and regulatory changes.

Investor Verification Checklist

• Verify the sufficiency of the $16.4 million cash balance against the company's burn rate and the timeline for the next capital raise.
• Confirm the status and terms of the remaining $20.4 million ATM capacity and $34.8 million Lincoln Park equity line.
• Review the detailed subgroup analysis of the SHINE study regarding the p-tau217 biomarker to assess the commercial viability of the AD indication.
• Monitor the impact of the discontinued MAGNIFY study on the company's overall pipeline valuation and resource allocation.
• Assess the risk of potential dilution from future equity offerings required to address the going concern warning.